Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders
- PMID: 29909246
- DOI: 10.1016/j.pharep.2018.02.003
Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders
Erratum in
-
Corrigendum to "Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders" [Pharmacol. Rep. 70 (2018) 661-667].Pharmacol Rep. 2019 Jun;71(3):465. doi: 10.1016/j.pharep.2018.10.015. Epub 2019 Apr 16. Pharmacol Rep. 2019. PMID: 31003158 No abstract available.
Abstract
Although adenosine plays a key role in multiple motor, affective, and cognitive processes, it has received less attention in the neuroscience field compared to other neurotransmitters (e.g., dopamine). In this review, we highlight the role of adenosine in behavior as well as its interaction with other neurotransmitters, such as dopamine. We also discuss brain disorders impacted by alterations to adenosine, and how targeting adenosine can ameliorate Parkinson's disease motor symptoms. We also discuss the role of caffeine (as an adenosine antagonist) on cognition as well as a neuroprotective agent against Parkinson's disease (PD).
Keywords: Adenosine; Caffeine; Dopamine; Motor processes; Parkinson’s disease.
Copyright © 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.J Neurol Sci. 2006 Oct 25;248(1-2):9-15. doi: 10.1016/j.jns.2006.05.003. Epub 2006 Jun 27. J Neurol Sci. 2006. PMID: 16806272 Review.
-
Pathophysiological roles for purines: adenosine, caffeine and urate.Prog Brain Res. 2010;183:183-208. doi: 10.1016/S0079-6123(10)83010-9. Prog Brain Res. 2010. PMID: 20696321 Free PMC article. Review.
-
Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.J Alzheimers Dis. 2010;20 Suppl 1:S205-20. doi: 10.3233/JAD-2010-091459. J Alzheimers Dis. 2010. PMID: 20182024 Review.
-
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.Drug News Perspect. 2003 Nov;16(9):597-604. doi: 10.1358/dnp.2003.16.9.829342. Drug News Perspect. 2003. PMID: 14702141 Review.
-
Caffeine; the Forgotten Potential for Parkinson's Disease.CNS Neurol Disord Drug Targets. 2017;16(6):652-657. doi: 10.2174/1871527315666161107091149. CNS Neurol Disord Drug Targets. 2017. PMID: 27823571 Review.
Cited by
-
Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients.Transl Neurodegener. 2022 Feb 7;11(1):6. doi: 10.1186/s40035-022-00280-7. Transl Neurodegener. 2022. PMID: 35125106 Free PMC article. Clinical Trial.
-
Comparative Computational and Experimental Detection of Adenosine Using Ultrasensitive Surface-Enhanced Raman Spectroscopy.Sensors (Basel). 2018 Aug 16;18(8):2696. doi: 10.3390/s18082696. Sensors (Basel). 2018. PMID: 30115871 Free PMC article.
-
Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease.Front Aging Neurosci. 2021 Nov 16;13:768156. doi: 10.3389/fnagi.2021.768156. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34867296 Free PMC article. Review.
-
Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases.J Biomed Sci. 2021 Oct 11;28(1):70. doi: 10.1186/s12929-021-00766-y. J Biomed Sci. 2021. PMID: 34635103 Free PMC article. Review.
-
Methoxy substituted 2-benzylidene-1-indanone derivatives as A1 and/or A2A AR antagonists for the potential treatment of neurological conditions.Medchemcomm. 2019 Jan 8;10(2):300-309. doi: 10.1039/c8md00540k. eCollection 2019 Feb 1. Medchemcomm. 2019. PMID: 30881617 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical